- Pepper Bio landed $6.5 million in seed funding led by NFX.
- The startup wants to improve the drug-discovery process for pharma companies using AI.
- Pepper Bio is also developing treatments itself and expects to begin clinical trials next year.
Drug discovery is expensive and time-consuming for pharmaceutical and biotech companies. From identifying the right biological targets implicated in a disease, to developing drugs that impact those targets through years-long clinical trials, the whole process can cost more than $2 billion.
Pepper Bio wants to reduce those costs by getting drug developers to the right targets faster, using what it calls a “transomics” approach.
Read on for the full story.